AccuStem Sciences Inc. announced the establishment of a joint clinical collaboration agreement with University Hospitals. Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test.

The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients' risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genetic tools to inform decisions earlier in the continuum of care. StemPrintER may be able to shift this paradigm by informing physicians of the most effective approaches to surgical or radiological treatment.

AccuStem and its clinical collaborators plan to present the data obtained under this agreement at scientific conferences and to publish the findings in peer-reviewed medical journals. Those activities will help to bolster the foundation of data for Stem printER and familiarize physicians with its utility and value in clinical decision making with the ultimate goal of improving patient outcomes and quality of life.